|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:ATCCode
|
N02AA03
|
|
gptkbp:brand
|
gptkb:Dilaudid
Hydromorph Contin
|
|
gptkbp:CASNumber
|
466-99-9
|
|
gptkbp:contraindication
|
respiratory depression
acute asthma
paralytic ileus
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II_(US)
|
|
gptkbp:derivedFrom
|
gptkb:morphine
|
|
gptkbp:discoveredBy
|
gptkb:Knoll
|
|
gptkbp:discoveredIn
|
1924
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasMolecularFormula
|
C17H19NO3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
hydromorphone
|
|
gptkbp:legalStatus
|
gptkb:Class_A_(UK)
gptkb:Schedule_8_(Australia)
prescription only
Schedule I (Canada)
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:meltingPoint
|
220°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
285.34 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:PubChem_CID
|
4447620
5284576
CHEMBL1530
DB00327
|
|
gptkbp:riskFactor
|
addiction
overdose
dependence
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
rectal
|
|
gptkbp:sideEffect
|
nausea
vomiting
constipation
drowsiness
respiratory depression
|
|
gptkbp:synonym
|
hydrochloride salt
dihydromorphinone
|
|
gptkbp:UNII
|
J280872D1V
|
|
gptkbp:usedFor
|
pain management
severe pain
|
|
gptkbp:bfsParent
|
gptkb:PCA_(patient-controlled_analgesia)
gptkb:Hydrocodone
gptkb:opioid_analgesics
gptkb:oxymorphone
gptkb:Dilaudid
gptkb:Palladone
gptkb:Desomorphine
|
|
gptkbp:bfsLayer
|
7
|